These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 36083110)

  • 1. Pharmacokinetics, metabolism and excretion of radiolabeled fostemsavir administered with or without ritonavir in healthy male subjects.
    Gorycki P; Magee M; Ackerman P; Miao X; Moore K
    Xenobiotica; 2022 Jun; 52(6):541-554. PubMed ID: 36083110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants.
    Moore K; Thakkar N; Magee M; Sevinsky H; Vakkalagadda B; Lubin S; Llamoso C; Ackerman P
    Antimicrob Agents Chemother; 2022 Apr; 66(4):e0225121. PubMed ID: 35315687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir.
    Lataillade M; Zhou N; Joshi SR; Lee S; Stock DA; Hanna GJ; Krystal M;
    J Acquir Immune Defic Syndr; 2018 Mar; 77(3):299-307. PubMed ID: 29206721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steady-state disposition of the nonpeptidic protease inhibitor tipranavir when coadministered with ritonavir.
    Chen L; Sabo JP; Philip E; Mao Y; Norris SH; MacGregor TR; Wruck JM; Garfinkel S; Castles M; Brinkman A; Valdez H
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2436-44. PubMed ID: 17485497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biotransformation and mass balance of tipranavir, a nonpeptidic protease inhibitor, when co-administered with ritonavir in Sprague-Dawley rats.
    Macha S; Chen L; Norris SH; Philip E; Mao Y; Silverstein H; Struble C; Beers W
    J Pharm Pharmacol; 2007 Sep; 59(9):1223-33. PubMed ID: 17883893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Temsavir, the Active Moiety of Fostemsavir.
    Magee M; Slater J; Mannino F; Ackerman P; Llamoso C; Moore K
    J Clin Pharmacol; 2021 Jul; 61(7):939-953. PubMed ID: 33368327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Temsavir, Active Moiety of Antiretroviral Agent Fostemsavir, on QT Interval: Results From a Phase I Study and an Exposure-Response Analysis.
    Lagishetty C; Moore K; Ackerman P; Llamoso C; Magee M
    Clin Transl Sci; 2020 Jul; 13(4):769-776. PubMed ID: 32027457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the pharmacokinetic drug-drug interaction between the antiretroviral agents fostemsavir and maraviroc: a single-sequence crossover study in healthy participants.
    Wire MB; Magee M; Ackerman P; Llamoso C; Moore K
    HIV Res Clin Pract; 2021 Dec; 23(1):1-8. PubMed ID: 35285786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents.
    Hsu A; Granneman GR; Bertz RJ
    Clin Pharmacokinet; 1998 Oct; 35(4):275-91. PubMed ID: 9812178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism and excretion of capravirine, a new non-nucleoside reverse transcriptase inhibitor, alone and in combination with ritonavir in healthy volunteers.
    Bu HZ; Pool WF; Wu EY; Raber SR; Amantea MA; Shetty BV
    Drug Metab Dispos; 2004 Jul; 32(7):689-98. PubMed ID: 15205383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug.
    Wire MB; Shelton MJ; Studenberg S
    Clin Pharmacokinet; 2006; 45(2):137-68. PubMed ID: 16485915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism and Disposition of Siponimod, a Novel Selective S1P
    Glaenzel U; Jin Y; Nufer R; Li W; Schroer K; Adam-Stitah S; Peter van Marle S; Legangneux E; Borell H; James AD; Meissner A; Camenisch G; Gardin A
    Drug Metab Dispos; 2018 Jul; 46(7):1001-1013. PubMed ID: 29735753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice.
    Li F; Wang L; Guo GL; Ma X
    Drug Metab Dispos; 2010 May; 38(5):871-8. PubMed ID: 20103582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absorption, metabolism, and excretion of darunavir, a new protease inhibitor, administered alone and with low-dose ritonavir in healthy subjects.
    Vermeir M; Lachau-Durand S; Mannens G; Cuyckens F; van Hoof B; Raoof A
    Drug Metab Dispos; 2009 Apr; 37(4):809-20. PubMed ID: 19131522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans.
    Takahashi RH; Choo EF; Ma S; Wong S; Halladay J; Deng Y; Rooney I; Gates M; Hop CE; Khojasteh SC; Dresser MJ; Musib L
    Drug Metab Dispos; 2016 Jan; 44(1):28-39. PubMed ID: 26451002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects.
    Ford SL; Chen YC; Lou Y; Borland J; Min SS; Yuen GJ; Shelton MJ
    Antimicrob Agents Chemother; 2008 Feb; 52(2):534-8. PubMed ID: 18056271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteers.
    Vourvahis M; Gleave M; Nedderman AN; Hyland R; Gardner I; Howard M; Kempshall S; Collins C; LaBadie R
    Drug Metab Dispos; 2010 May; 38(5):789-800. PubMed ID: 20124396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fostemsavir: The first oral attachment inhibitor for treatment of HIV-1 infection.
    Chahine EB
    Am J Health Syst Pharm; 2021 Feb; 78(5):376-388. PubMed ID: 33547469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans.
    Kumar GN; Jayanti VK; Johnson MK; Uchic J; Thomas S; Lee RD; Grabowski BA; Sham HL; Kempf DJ; Denissen JF; Marsh KC; Sun E; Roberts SA
    Pharm Res; 2004 Sep; 21(9):1622-30. PubMed ID: 15497688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.